Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

XPhyto Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Accesswire August 2, 2022

XPhyto Therapeutics Announces Offering of Units of the Company

Accesswire July 22, 2022

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Accesswire July 18, 2022

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Accesswire July 15, 2022

Prof. Dr. Raimar Loebenberg Receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Accesswire June 27, 2022

XPhyto Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to Its European Team

Accesswire June 8, 2022

XPhyto Reports Product Developments on Platform-Based Rotigotine Transdermal Patch for Parkinson's Disease

Accesswire May 9, 2022

XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease

Accesswire April 11, 2022

XPhyto Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease

Accesswire April 4, 2022

XPhyto Closes First Tranche of Financing

Accesswire March 31, 2022

XPhyto Provides Progress Update on Psychedelic Medicine Programs and Novel Compounds Milestone

Accesswire February 22, 2022

XPhyto Reports on its Three Primary Business Divisions

Accesswire February 8, 2022

XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as Part of Multi-Product Rollout Strategy

Accesswire February 1, 2022

XPhyto Provides Update on Integration of 3a-diagnostics GmbH

Accesswire January 24, 2022

XPhyto Announces Head of Sales, Europe

Accesswire January 17, 2022

XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia

Accesswire January 13, 2022

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Accesswire January 10, 2022

XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips

Accesswire December 15, 2021

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Accesswire December 6, 2021

XPhyto Therapeutics Announces Stock Option Grants

Accesswire December 3, 2021